Agios presents positive results from phase 3 energize-t study of mitapivat at ash 2024 and provides regulatory update on mitapivat

– energize-t study achieved primary and all key secondary endpoints in adult patients with transfusion-dependent alpha- or beta-thalassemia –

ASH Ratings Summary

ASH Quant Ranking